Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome

American Journal of Gastroenterology

Volumn 105, Issue 2, 2010, Pages 280-288

  Ford, Alexander C ^a   Guyatt, Gordon H ^a   Talley, Nicholas J ^b   Moayyedi, Paul ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; CISAPRIDE; DOMPERIDONE; PEPPERMINT OIL; SPASMOLYTIC AGENT; TEGASEROD;

ACCURACY; CASE REPORT; CLINICAL TRIAL; DATA EXTRACTION; FIBER; FOLLOW UP; HUMAN; IRRITABLE COLON; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

DATA COLLECTION; HUMANS; IRRITABLE BOWEL SYNDROME; META-ANALYSIS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; REVIEW LITERATURE AS TOPIC; SELECTION BIAS;

EID: 76349096266     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.658     Document Type: Review

References (40)

1. Moher D, Cook D J, Eastwood S et al. Improving the qualityofreports of meta-analyses of randomised controlled trials:the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354:1896-1900
2. Jadad A R, Cook D J, Jones A et al. Methodology and reports of systematic reviews and meta-analyses:a comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998; 280:278-280
3. Jadad A R, Moher M, Browman G P et al. Systematic reviews and meta-analyses on treatment of asthma:critical appraisal. BMJ 2000; 320:537-540
4. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs:systematic review. BMJ 2006;333:782.
5. Gotzsche P C, Hrobjartsson A, Maric K et al.Data extraction errors in meta-analyses that use standardized mean diferences. JAMA 2007;298:430-437
6. Jones AP, Remmington T, Wi lliamson PR et al. High prevalence but low impact of data extraction and reporting errors were found in Cochrane systematic reviews. J Clin Epidemiol 2005; 58:741-742
7. Spiller R, Aziz Q, Creed FEA et al. Guidelines on the irritable bowel syndrome:mechanisms and practical management. Gut 2007;56:1770-1798
8. Cremonini F, Delgado-Aros S, Camilleri M. Eficacy of alosetron in irritable bowel syndrome:a meta-analysis of randomized controlled trials. Neuro-gastroenterol Motil 2003;15:79-86.
9. Elbourne D R, Altman D G, Higgins JP T et al. Meta-analyses involving cross-over trials:methodological issues. Int J Epidemiol 2002; 31:140-149
10. Bijkerk CJ, Muris JWM, Knottnerus JA et al. Systematic review:the role of dif erent types of f bre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:245-251
11. B r a n d t L J, B j o r k m a n D, F e n n e r t y M B et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97 (Suppl):S7-S26.
12. Jackson JL, O 'Malley P G, Tomkins G et al.T reatm en t o f fu n ctio n al gastrointestinal disorders with antidepressant medications:a meta-analysis. Am J Med 2000;108:65-72.
13. Jaliwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome:a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-147
14. Lesbros-Pantofick o va D, M ich etti P, F ried M et al. M eta-an alysis:the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253-1269
15. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome:a critical review and meta-analysis. Am J Gastroenterol 1998;93:1131-1135
16. Poynard T, Regimbeau C, Benhamou Y. M eta-an alysis o f sm o o th m u scle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-361
17. Quartero AO, Meineche-Schmidt V, Muris J et al. Bulking agents, antispas-modic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005, CD003460.
18. T ack J, F rie d M, H o u gh t o n L A et al. Systematic review:the eficacy of treatments for irritable bowel syndrome \-a European perspective. Aliment Pharmacol Ther 2006;24:183-205
19. Evans B W, Clark W K, Moore D J et al. Thegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007, CD003960.
20. Jones B W, Moore D J, Robinson SM et al. A systematic review of tegaserod for the treatment of irritable bowel syndrome. J Clin Pharmacol 2002;27:343-352
21. Anonymous. Systematic review on the management of irritable bowel syndrome in the European Union. Eur J Gastroenterol Hepatol 2007;19 (Suppl 1):S11-37.
22. Kruis W, Weinzierl M, Schussler P et al. Comparison of the therapeutic ef ects of wheat bran and placebo in patients with the irritable bowel syndrome. Digestion 1986;34:196-201.
23. Nigam P, Kapoor K K, Rastog C K et al. D if erent therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India 1984;32:1041-1044
24. Manning AP, Heaton KW, Harvey RF et al. Wheatfbre and irritable bowel syndrome:a controlled trial. Lancet 1977;310:417-418
25. Lucey M R, Clark M L, Lowndes JO et al.Is b ran eficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut 1987;28:221-225
26. L i u J-H, C h e n G-H, Y e h H-Z et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome:a prospective, randomized trial. J Gastroenterol 1997;32:765-768
27. Ghidini O, Saponati G, Intrieri L. Single drug treatment for irritable colon:rociverine versus trimebutine maleate. Curr T er Res Clin Exp 1986;39:541-548
28. Gilvarry J, Kenny A, Fielding J F. T e non-ef ect of pirenzipine in dietary resistant irritable bowel syndrome. Ir J Med Sci 1989;158:262.
29. Mitchell S A, Mee A S, Smith G D et al. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome:results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol T er 2002; 16:1187-1195
30. Piai G, Mazzacca G. Prif nium bromide in the treatment of the irritable colon syndrome. Gastroenterology 1979;77:500-502
31. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981;3:153-156
32. D'Arienzo A, D'Agostino L. L'ottilonio bromuro nel trattamento della síndrome del colon irritabile. Rass Int Clin Ther 1980;60:649-56.
33. Virat J, Hueber D. C olopathy pain and dicetel. Prat Med 1987; 43:32-34
34. Bergmann M, Heddergott A, Schlosser T. Die therapie des colon irritabile mit trimipramin (Herphonal) \-Eine kontrollierte studie. Z Klin Med 1991;46:1621-1628
35. Baldi F, Corinaldesi R, Ferrarini F et al. Clinical and functional e valuation of octilonium bromide in the treatment of irritable bowel syndrome:a double-blind controlled trial. Clin Trials J 1983; 20:77-88.
36. Castiglione F, Daniele B, Mazzacca G. T erapeutic strategy for the irritable bowel syndrome. Ital J Gastroenterol 1991;23 (Suppl 1):53-55
37. 4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS). Digestion 1998;59 (Suppl 3):20.
38. Schutze K, Brandstatter G, Dragosics B et al. Double-blind study of the ef ect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol T er 1997;11:387-394
39. Drossman D A, Camilleri M, Mayer E A et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131 (Pubitemid 35408332)
40. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions:Version 5.0.0. www.cochrane-handbook.org, 2008.